From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer.
Centre for Biosystems & Genomic Network Medicine - CBS.GenNetMed University of Ioannina, Ioannina, GR 451 10, Greece.
Georgios D
GD
Lianos
Dimitrios H
DH
Roukos
D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D053263:Gene Regulatory Networks / Q000187:drug effects; D023281:Genomics; D006801:Humans; D008453:Maytansine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D014158:Transcription, Genetic / Q000187:drug effects*; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine